Altogether, these study results show that the participation of BCMA in SLE pathogenesis is more critical than previously thought, and we consider BCMA particularly relevant for current clinical trials targeting the cytokines BAFF/APRIL. The gene discussed is TNFRSF17; the disease is systemic lupus erythematosus.